Streetbeat News

Stock Prices

AAPL

NFLX

T

TMUS

T-Mobile US, Inc (NASDAQ:TMUS) reported strong Q2 fiscal 2024 results, beating analyst estimates on both earnings and revenue. The company saw significant growth in postpaid net account additions and adjusted free cash flow. T-Mobile also raised its full-year outlook for postpaid net customer additions and adjusted free cash flow. The company's Go5G plans, which include streaming services from Netflix and Apple, have been popular among customers.

Portfolio Pulse from Anusuya Lahiri

July 31, 2024 | 12:52 pm

TEVA

Teva Pharmaceuticals Industries shares are trading higher after the company reported better-than-expected Q2 financial results and issued FY24 guidance.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 12:51 pm

SW

Smurfit Westrock shares are trading lower after the company reported worse-than-expected Q2 EPS results.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 12:47 pm

ONON

On Holdings shares are trading higher after Raymond James initiated coverage on the stock with an Outperform rating and announced a $46 price target.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 12:46 pm

ACIU

AC Immune SA (NASDAQ:ACIU) unveiled a novel therapeutic antibody drug conjugate technology called morADC at the AAIC 2024. This new class of drug-candidates combines proprietary brain-penetrant small molecule Morphomers® with SupraAntigen® monoclonal antibodies, showing significant synergies in increasing blood-brain barrier penetration and potency in inhibiting protein aggregation.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 12:43 pm

GRPN

Groupon (NASDAQ:GRPN) reported Q2 losses of $(0.02) per share, missing the analyst estimate of $0.03. However, sales of $124.61M beat the $121.66M estimate. Losses improved by 80% year-over-year, but sales decreased by 3.48%.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 12:43 pm

RNXT

RenovoRx has published positive early-stage data on its TAMP therapy for locally advanced pancreatic cancer. The therapy, combined with prior chemoradiation, shows a 27-month overall survival rate. An ongoing Phase III trial is evaluating the targeted chemotherapy delivery. The study was published in The Oncologist.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 12:41 pm

JCI

Johnson Controls International (NYSE:JCI) reported Q3 earnings with an EPS beat but missed on sales. The company announced CEO succession plans and a new board member from Elliott Management. JCI shares are trading higher by 8.66% premarket.

Portfolio Pulse from Nabaparna Bhattacharya

July 31, 2024 | 12:41 pm

MO

Altria Group shares are trading lower after the company reported worse-than-expected Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 12:40 pm

VMEO

Vimeo has launched an AI-powered video translation solution that translates video, audio, and captions into multiple languages while replicating the original speakers' voices. This innovation aims to reduce the time and cost associated with traditional translation services.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2024 | 12:39 pm